Clearline Capital’s CytomX Therapeutics CTMX Stock Holding History

Clearline Capital’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-196,583	Closed	-$429K	–	149
2024 Q1	$429K	Hold	196,583	–	–	0.02%	113
2023 Q4	$305K	Hold	196,583	–	–	0.02%	94
2023 Q3	$254K	Hold	196,583	–	–	0.02%	120
2023 Q2	$338K	Hold	196,583	–	–	0.02%	107
2023 Q1	$297K	Hold	196,583	–	–	0.04%	96
2022 Q4	$315K	Hold	196,583	–	–	0.06%	108
2022 Q3	$285K	Hold	196,583	–	–	0.03%	126
2022 Q2	$360K	Buy	196,583 +5,983	+3%	+$11.5K	0.05%	117
2022 Q1	$509K	Buy	190,600 +45,600	+31%	+$175K	0.06%	101
2021 Q4	$628K	Buy	+145,000	New	+$849K	0.07%	106

Other funds holding CTMX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Clearline Capital's CTMX Position: Q2 2024 in Review

Clearline Capital sold out of CytomX Therapeutics (CTMX) in Q2 2024, closing a stake of 196,583 shares — an estimated $429K sold.

Clearline Capital first reported a position in CTMX in Q4 2021 and held it in 10 quarters. The position peaked at $628K in Q4 2021. 74 funds tracked by Wall St. Rank hold CTMX as of Q2 2024.

Clearline Capital reported no remaining CytomX Therapeutics position as of Q2 2024 after selling out during the quarter.
Clearline Capital sold 196,583 CytomX Therapeutics shares in Q2 2024, an estimated $429K.
Clearline Capital first reported a position in CytomX Therapeutics in Q4 2021 and held it in 10 quarters.
Clearline Capital's CytomX Therapeutics position peaked at $628K in Q4 2021.
74 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2024.

Based on Clearline Capital's 13F filing for Q2 2024, filed 15 Aug 2024.